Sipuleucel-T: Prototype for development of anti-tumor vaccines

Current Oncology Reports

Volumn 13, Issue 2, 2011, Pages 112-119

  Carballido, Estrella ^a   Fishman, Mayer ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cell vaccine; Immunotherapy; PAP GM CSF fusion protein; Prostate cancer; Vaccines

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BEVACIZUMAB; CALCITRIOL; CANCER ANTIBODY; CYTOTOXIC AGENT; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROVENGE; SATRAPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG APPROVAL; DRUG EFFICACY; EX VIVO STUDY; HUMAN; IMMUNE DEFICIENCY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; TREATMENT OUTCOME; VACCINE PRODUCTION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 79955814192     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0152-5     Document Type: Review

References (36)

1. O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol 2010, 28:18s: abstract# 4. This positive phase 3 trial showed that ipilimumab alone or combined with immunotherapy resulted in a significant improvement in OS. Ipilimumab trial is open for prostate cancer patients.
2. National clinical trial website. Available at www.clinicaltrials.gov. NCT 01057810-Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM 2010, 5:411-22. This is the pivotal trial that showed a difference in the median survival as well as immunologic effects in the treated population, including antibody and T cell-specific activity to P2024 and PAP. This has the most definitive dataset.
4. Small EJ, Schellhammer PF, Higano CS et al. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer. J Clin Oncol 2006, 24:3089-94. (Pubitemid 46638945)
5. Higano CS, Schellhammer PF, Small EJ, Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. Cancer 2009,115(16):3670-79. This paper aggregates the data from two phase 3 trials with sipuleucel-T.
6. Burch PA, Breen JK, Buckner JC, et al. Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer. Clinical Cancer Research 2000, 6: 2175-82. (Pubitemid 30399182)
7. Drake CG, Antonarakis ES. Update: Immunological Strategies for Prostate Cancer. Curr Urol Rep 2010, 11:202-07. This is a recent review of prostate cancer immunotherapy.
8. Almand B, Clark JI, Nikitina E et al. Increase production of immature myeloid cells in cancer patients: a mechanism of immnosuppression in cancer. The Journal of Immunology 2001, 166: 678-89. (Pubitemid 32038493)
9. Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 2009, 9(12):1565-75.
10. Zhang H, Melamed J, Wei P et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immunity 2003.3:2
11. Sanda MG, Restifo NP, Walsh JC et al. Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. J Natl Cancer Inst 1995; 87(4):280-85.
12. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114(8): 1545-52.
13. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114 (8):1537-44.
14. Chappell DB, Restifo NP. T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998, 47(2):65-71.
15. Nefedova Y, Fishman M, Sherman S, el al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007, 67(22):11021-8.
16. Curti A, Trabanelli S, Salvestrini V, et al. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113(11): 2394-2401.
17. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nature Reviews Cancer 2006, 6:521-534. (Pubitemid 43980541)
18. Lahdenranta J, Hagendoorn J, Padera TP et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009, 69(7):2801-8.
19. Deandreon company: product information available at www.provenge.com
20. Stewart FP, DelaRosa CP, Sheikh N et al. Correlation between product parameters and overall survival in 3 trials of Sipuleucel-T, an Autologous Cellular Immunotherapy for the treatment of Prostate Cancer. abstract #4552 Presented at ASCO Annual Meeting 2010 Chicago, Illinois; June 4-8, 2010. This article presents how the difference in quantification of CD54+ dendritic cells in the apheresis product versus the ready-to-ship sipuleucel-T product correlates with overall survival.
21. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20. (Pubitemid 39315318)
22. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5.
23. Tannock IF, de Wit R, Berry WR, Horti J et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM 2004;351(15):1502-12. (Pubitemid 39315317)
24. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17(11): 3461-67. (Pubitemid 29517916)
25. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. J Clin Oncol 2009; 27(32): 5431-5438. Data presented in this trial showed that satraplatin offers PSA response, tumor regression, and improved median time to progression in pretreated patients, but with no OS increment.
26. Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab inmen with metastatic castration-resistant prostate cancer: Survival results of CALGB 90401. J Clin Oncol 2010; 28:18s. abstract LBA4511.
27. Beer TM, Ryan CW, Venner PM, et al. Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. J Clin Oncol 2007;25(6):669-74. (Pubitemid 350002922)
28. Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone for patients with progressive castration-resistant prostate cancer: Results from the phase III ASCENT2 trial. J Clin Oncol 2010; 28:15s:abstract # 4509.
29. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells. J Clin Oncol 2000;18(23):3894-3903.
30. Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Abstract LBA150. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28, 2009.
31. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Abstract 7. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28,2009.
32. National clinical trial website. Available at www.clinicaltrials.gov. NCT 01057810 - A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating DCVax(Tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer
33. De Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147-54. This article shows the clinical antitumor activity and improved overall survival that this new tubulin-binding taxane drug has in CRPC.
34. Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009;15(18):5937-44. This is an extension of the sipuleucel-T platform to another antigen.
35. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145-54.
36. Doehn C, Richter A, Theodor RA, et al. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase III trial. European Urology Supplements 2006; 5(2);286.